Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice

Journal of Pathology

Volumn 211, Issue 1, 2007, Pages 86-94

  El Karef, A ^a   Yoshida, T ^a   Gabazza, E C ^a   Nishioka, T ^a   Inada, H ^a   Sakakura, T ^a   Imanaka Yoshida, K ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Hepatic stellate cell; Immune mediated hepatitis; Interleukin 4; Knockout mice; Liver fibrosis; Tenascin C; Transforming growth factor

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; PROCOLLAGEN; PROCOLLAGEN TYPE 1; PROCOLLAGEN TYPE 3; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; STELLATE CELL; UPREGULATION; WILD TYPE;

ANIMALS; CONCANAVALIN A; FEMALE; HEPATITIS, CHRONIC; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-4; LIVER CIRRHOSIS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROCOLLAGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33846224310     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2099     Document Type: Article

References (53)

1. Friedman S. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
2. Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000;35:665-672.
3. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993;178:17-25.
4. Napoli J, Bishop GA, McCaughan W. Increased intrahepatic messenger RNA expression of interleukins 2, 6 and 8 in human cirrhosis. Gastroenterology 1994;107:789-798.
5. Abrignani S. Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis. Semin Liver Dis 1997;17:319-322.
6. Ramadori G, Saile B. Mesenchymal cells in the liver - one cell type or two? Liver 2002;22:283-294.
7. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
8. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-499.
9. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-259.
10. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000;19:581-596.
11. Van Eyken P, Sciot R, Desmet VJ. Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohisto-chemical study. J Hepatol 1990;11:43-52.
12. Yamada S, Ichida T, Matsuda Y, Miyazaki Y, Hatano T, Hata K, et al. Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. Liver 1992;12:10-16.
13. Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999;117:1205-1221.
14. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-1831.
15. Fukamauchi F, Malaga N, Wang YJ, Sato S, Youshiki A, Kusakabe M. Abnormal behavior and neurotransmissions of tenascin gene knockout mouse. Biochem Biophys Res Commun 1996;221:151-156.
16. Fukamauchi F, Kusakabe M. Preprotachykinin A and cholecystokinin mRNAs in tenascin-gene knockout mouse brain. Neuropeptides 1997;31:199-201.
17. Cifuentes-Diaz C, Velasco E, Meunier FA, Goudou D, Belkadi L, Faille L, et al. The peripheral nerve and the neuromuscular junction are affected in the tenascin-C-deficient mouse. Cell Mol Biol 1998;44:357-379.
18. Nakao N, Hiraiwa N, Yoshiki A, Ike F Kusakabe M. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol 1998;52:1237-1245.
19. Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Obashi T, Irie S, et al. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol 1998;111:930-935.
20. Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K. Shimpo H, et al. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 2005:65:737-742.
21. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005;167:71-80.
22. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology 1989;10:84-92.
23. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997;94:10663-10668.
24. Rubin E. Hutterer F, Popper H. Experimental hepatic fibrosis without hepato-cellular regeneration. Am J Pathol 1968;52:111-120.
25. Milani S, Herbst H, Schuppan D, Kim KY, Riecken EO, Stein H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 1990;98:175-184.
26. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, Co TM, et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 1994;153:753-759.
27. Kimura K, Ando K, Ohnishi H, Ishikawa T, Kakumu S, Takemura M, et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol 1999;11:1491-1500.
28. Louis H, Le Moine A, Quertinmont E, Peny MO, Geerts A, Goldman M, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000;31:381-390.
29. Kalembey I, Yoshida T, Iriyama K, Sakakura T. Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: an in situ hybridization study. Int J Dev Biol 1997;41:569-573.
30. James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 1990;10:1-5.
31. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
32. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90:196-203.
33. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994;179:1529-1537.
34. Sass G. Heinlein S, Agli A, Bang R, Schumann J, Tiegs G. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 2002;19:115-120.
35. Mizuhara H, Uno M, Seki N, Yamashita M, Yamaoka M, Ogawa T, et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996;23:1608-1615.
36. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996;111:462-471.
37. Nicoletti F, Zaccone P, Xiang M, Magro G, Di Mauro M, Di Marco R, et al. Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine 2000;12:315-323.
38. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 1991;266:14831-14834.
39. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 1997;137:755-765.
40. 2+ signaling in Jurkat T lymphocytes. J Immunol 1997;158:1618-1627.
41. Lopez-Moratalla N, del Mar Calonge M, Lopez-Zabalza MJ, Perez-Mediavilla LA, Subira ML, Santiago E. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. Biochim Biophys Acta 1995;1265: 181-188.
42. Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D'Alessandro-Gabazza CN, Bruno NE, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol (in press).
43. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006;26:8-22.
44. Toma N, Imanaka-Yoshida K, Takeuchi T, Matsushima S, Iwata H, Yoshida T, et al. Tenascin-C-coated platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model. J Neurosurg 2005;103:681-686.
45. Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995;96:447-455.
46. Saile B, Matthes N, Neubauer K, Eisenbach C, El-Armouche H, Dudas J, et al. Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2002;283:G435-G444.
47. Inagaki Y, Truter S, Greenwel P, Rojkind M, Unoura M, Kobayashi K, et al. Regulation of the alpha 2(I) collagen gene transcription in fat-storing cells derived from a cirrhotic liver. Hepatology 1995;22:573-579.
48. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-12724.
49. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859-867.
50. Pearson CA, Pearson D, Shibahara S, Hofsteenge J, Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-beta. EMBO J 1988;7:2977-2982.
51. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metallo-proteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta 1. Int J Cancer 2003;105:53-60.
52. Ilunga K, Nishiura R, Inada H, El-Karef A, Imanaka-Yoshida K, Sakakura T, et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 2004;85:373-379.
53. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, et al. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int 2006;26:311-318.